Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Glioma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Paclitaxel 68Carboplatin 64pembrolizumab 32Cyclophosphamide 32Bevacizumab 27liposomal doxorubicin 24Cisplatin 24Topotecan 21Gemcitabine 21olaparib 18fludarabine 17Taxes 16Docetaxel 15Nivolumab 14Doxorubicin 14niraparib 13veliparib 12Albumin-Bound Paclitaxel 11aldesleukin 9Filgrastim 9fludarabine phosphate 8durvalumab 8Oxaliplatin 8Fluorouracil 8Drug Therapy 8sargramostim 7Peripheral Blood Stem Cell Transplantation 7Magnetic Resonance Spectroscopy 7Leucovorin 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Ovarian Neoplasms × Phantoms, Imaging × Clear all
NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡